Determination of olanzapine in plasma by high-performance liquid chromatography using ultraviolet absorbance detection

被引:93
作者
Dusci, LJ
Hackett, LP
Fellows, LM
Ilett, KF
机构
[1] Western Australian Ctr Pathol & Med Res, Clin Pharmacol & Toxicol Lab, Nedlands, WA 6009, Australia
[2] Graylands Hosp, Dept Pharm, Graylands 6010, Australia
[3] Univ Western Australia, Dept Pharmacol, Crawley 6009, Australia
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2002年 / 773卷 / 02期
关键词
olanzapine;
D O I
10.1016/S1570-0232(02)00164-2
中图分类号
Q5 [生物化学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
A rapid method for the determination of olanzapine in plasma using high-performance liquid chromatography with ultra violet detection is described. Olanzapine was extracted from plasma with a mixture of hexane/dichloromethane (85:15), and then back extracted into phosphate buffer pH 2.8. Separation was achieved on a RP Select B C-18 column and commonly administered drugs did not interfere with the assay. The limit of quantitation was 1.5 mug/1 and the inter-day and intra-day relative standard deviations were less than 10%. Olanzapine was shown to be stable in plasma for up to 7 days when stored at 4 degreesC. Moreover, the addition of ascorbic acid was not necessary for the achievement of chemical stability during storage, or during the assay procedure. The method has been used to measure olanzapine concentrations in patients treated with various doses of the drug varying from 5 to 40 mg/day. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:191 / 197
页数:7
相关论文
共 16 条
[1]
Plasma level monitoring of olanzapine in patients with schizophrenia: Determination by high-performance liquid chromatography with electrochemical detection [J].
Aravagiri, M ;
Ames, D ;
Wirshing, WC ;
Marder, SR .
THERAPEUTIC DRUG MONITORING, 1997, 19 (03) :307-313
[2]
Olanzapine - Pharmacokinetic and pharmacodynamic profile [J].
Callaghan, JT ;
Bergstrom, RF ;
Ptak, LR ;
Beasley, CM .
CLINICAL PHARMACOKINETICS, 1999, 37 (03) :177-193
[3]
ANALYSIS OF OLANZAPINE IN HUMAN PLASMA UTILIZING REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION [J].
CATLOW, JT ;
BARTON, RD ;
CLEMENS, M ;
GILLESPIE, TA ;
GOODWIN, M ;
SWANSON, SP .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 668 (01) :85-90
[4]
Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection [J].
Chiu, JA ;
Franklin, RB .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1996, 14 (05) :609-615
[5]
Kassahun K, 1997, DRUG METAB DISPOS, V25, P81
[6]
Instability of olanzapine in calf serum [J].
Lakso, HÅ .
THERAPEUTIC DRUG MONITORING, 2001, 23 (04) :454-455
[7]
Lund B C, 2000, Expert Opin Pharmacother, V1, P305, DOI 10.1517/14656566.1.2.305
[8]
Nemeroff CB, 1997, J CLIN PSYCHIAT, V58, P45
[9]
Olanzapine serum concentrations in psychiatric patients given standard doses: The influence of comedication [J].
Olesen, OV ;
Linnet, K .
THERAPEUTIC DRUG MONITORING, 1999, 21 (01) :87-90
[10]
Determination of olanzapine in serum by high-performance liquid chromatography using ultraviolet detection considering the easy oxidizability of the compound and the presence of other psychotropic drugs [J].
Olesen, OV ;
Linnet, K .
JOURNAL OF CHROMATOGRAPHY B, 1998, 714 (02) :309-315